Abstract:ABSTRACT Thymidine analogs, including 3′-azido-3′-deoxythymidine (AZT) and 2′,3′-dideoxy-3′-deoxythymidine (D4T), are important antiretroviral agents. To exert antiretroviral activity, these analogs undergo a stepwise phosphorylation intracellularly to the active triphosphate metabolites. We previously reported that 4′-substituted D4T with an ethynyl group (i.e., 4′-ethynyl D4T) increased the anti-human immunodeficiency virus (HIV) activity and was active against multidrug-resistant HIV strains. 4′-Ethynyl D4T is a better substrate for phosphorylation by human thymidine kinase 1 than D4T is. In this report, we first studied the enzymes involved in the phosphorylation of 4′-ethynyl D4T from monophosphate to triphosphate metabolites. The 4′-ethynyl D4TMP is phosphorylated by recombinant human TMP kinase with a K m of 19 ± 4 μM and a k cat of 0.007 ± 0.001 s −1 ; the relative efficiency is about 9 and 15% of those of D4TMP and AZTMP, respectively. Several enzymes from crude cellular extracts, including nucleoside diphosphate kinase, pyruvate kinase, creatine kinase, and 3-phosphoglycerate kinase, could phosphorylate 4′-ethynyl D4T-diphosphate. The relative phosphorylation efficiencies of 4′-ethynyl D4TDP were about 3 to 25% of those of D4TDP and were generally similar to those of AZTDP. In T-lymphoid cell lines, there was a preponderant accumulation of 4′-ethynyl D4TMP, suggesting that TMP kinase could be the rate-limiting enzyme in the metabolism of 4′-ethynyl D4T. Although the same enzymes are involved in the stepwise phosphorylation of thymidine analogs, their behaviors in phosphorylating metabolites of 4′-ethynyl D4T are different from those of D4T and AZT. Qualitatively, the metabolism of 4′-ethynyl D4T is more similar to that of AZT than to that of its progenitor, D4T.

New and Efficient Approach to Aryl Phosphoramidate Derivatives of AZT/d4T as Anti-HIV Prodrugs

One-Pot Synthesis of Aryl Phosphoramidate Derivatives of Azt/D4t As Anti-Hiv Prodrugs

Synthesis of Novel 5′-Hydrogenphosphonothioate Derivatives of AZT, d4T and ddI

ONE POT SYNTHESIS OF ARYL THIOPHOSPHORAMIDATE DERIVATIVES OF AZT

Novel and Convenient Approach to Synthesis of AZT/d4T H‐phosphonates

A Convenient Route to Symmetric Phosphate, Phosphorothioate, and Phosphoroselenoate of AZT and D4T

Synthesis of Novel Dimeric Steroidal-nucleoside Phosphoramidates

Synthesis and spectroscopic analysis of 2′,3′-didehydro- 2′,3′-dideoxythymidine (d4T) 5′-thiophosphoramidates

Synthesis of AZT/d4T Boranophosphates as Anti-HIV Prodrug Candidates

Synthesis of AZT 5′-O-hydrogen phospholipids and their derivatives

Comparison of the Phosphorylation of 4′-Ethynyl 2′,3′-Dihydro-3′-deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Synthesis, In Vitro Biological Stability, and Anti-HIV Activity of 5-Halo (or Methoxy)-6-Alkoxy (Azido or Hydroxy)-5,6-Dihydro-2′,3′-Didehydro-3′-Deoxythymidine Diastereomers as Potential Prodrugs of 2′,3′-Didehydro-3′-deoxythymidine (D4T)

Novel approach to the synthesis of AZT 5′-O-hydrogen phospholipids

Convenient and Efficient Approach to Di- and Trideoxyribonucleotide N3′→P5′ Phosphoramidates

Membrane Permeable, Bioreversibly Modified Prodrugs of Nucleoside Diphosphate-γ-Phosphonates

Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: from Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs

One-pot Synthesis of the O-(3-Diosgenin) O′-[5′-(3′-Azido-3′-deoxythymidine)]-H-phosphonate

Synthesis, in Vitro Anticancer Evaluation, and Interference with Cell Cycle Progression of N-Phosphoamino Acid Esters of Zidovudine and Stavudine

Improving the Anti-Hiv-1 Activity and Solubility of Poorly Water-Soluble DAPYs by Heteroaromatic Replacement Strategy: from Naphthalene-Dapys to Quinoline-Dapys.

Synthesis and Biological Evaluation of 4-(Hydroxyimino)arylmethyl Diarylpyrimidine Analogues As Potential Non-Nucleoside Reverse Transcriptase Inhibitors Against HIV